Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PCV20 · Prevnar 20

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, · developed by Wyeth Pharmaceuticals LLC

Approved FDA, Jun 2021
PFE Developer
4 Registered trials

What is PCV20?

PCV20 is a 20-valent pneumococcal conjugate vaccine containing capsular polysaccharides from 20 Streptococcus pneumoniae serotypes, each conjugated to the CRM197 carrier protein. It is given intramuscularly to induce active immunity against pneumococcal disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Prevnar 20
Drug type
Vaccine (Recombinant protein vaccine)
Targets
Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, (antigen)
Mechanism
Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B,
Therapy area
Infectious disease
Developer
Wyeth Pharmaceuticals LLC (PFE)
Also in trials of
MRK, PCVX
FDA status
Approved as Prevnar 20 (June 8, 2021), BLA125731

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07794748 Phase 3 Pneumococcal Disease Active not recruiting PFE
NCT07425392 Phase 3 Pneumococcal Vaccines Active not recruiting PCVX
NCT06151288 Phase 1/2 Pneumococcal Vaccines Completed PCVX
NCT05297578 Phase 2 Pneumococcal Vaccines Completed PCVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HealthyPneumococcal DiseasePneumococcal Vaccines

More from Wyeth Pharmaceuticals LLC

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind PCV20

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.